Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8885696 | 0.98 | TSHR (0.54) | EPHX2TSHRNPC1RAB9ACYP1A2 | |
| SCHEMBL27672250 | 0.94 | EPHX2 (0.53) | EPHX2TSHRCYP1A2ALDH1A1EPHX1 | |
| SCHEMBL28136578 | 0.94 | TSHR (0.54) | EPHX2TSHRNPC1RAB9AALDH1A1 | |
| SCHEMBL10977640 | 0.93 | EPHX2 (0.55) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL15369868 | 0.93 | EPHX2 (0.55) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL10939248 | 0.93 | EPHX2 (0.55) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL10781670 | 0.93 | EPHX2 (0.55) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL3904358 | 0.92 | TSHR (0.52) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL13546168 | 0.91 | EPHX2 (0.53) | EPHX2TSHRALDH1A1EPHX1SIGMAR1 | |
| SCHEMBL4942582 | 0.90 | TSHR (0.58) | EPHX2TSHRALDH1A1SMN1; SMN2KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867023-B2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2005-03-15 | — | — | US | claimed |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-06-27 | — | — | US | claimed |
| EP-1201763-A2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | claimed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-4076649-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-114828958-A | Cycloalkyl-containing carboxylic acids and use thereof | 里米诺生物科学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124272-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
| US-9493471-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-9133199-B2 | Pyrimidine derivatives as protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20030125306-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2003-07-03 | — | — | US | disclosed |
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | CIRCAGEN PHARMACEUTICAL, A MARYLAND CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-6495719-B2 | FOR USE IN THERAPY OF CANCER, HEMATOLOGICAL DISORDERS, SUCH AS HEMATOPOIESIS, AND GENETIC RELATED METABOLIC DISORDERS, SUCH AS, CYSTIC FIBROSIS AND ADRENOLEUKODYSTROPHY | CIRCAGEN PHARMACEUTICAL | 2002-12-17 | — | — | US | disclosed |
| US-20020143196-A1 | Histone deacetylase inhibitors | ERRANT GENE THERAPEUTICS, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020143052-A1 | Histone deacetylase inhibitors | ANGELA CHEN SABELLA | 2002-10-03 | — | — | US | disclosed |
| US-20020143037-A1 | Histone deacetylase inhibitors | CIRCAGEN PHARMACEUTICAL, A DELAWARE CORPORATION | 2002-10-03 | — | — | US | disclosed |
| WO-2002076941-A2 | HISTONE DEACETYLASE INHIBITORS | CIRCAGEN PHARMACEUTICAL (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-06-27 | — | — | US | disclosed |
| EP-1201763-A2 | Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material | CANON KABUSHIKI KAISHA (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083521-A1 | Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy) | ZFX, HDAC5, ZNF277 | EPHX2 1309/4885TSHR 3876/4885NPC1 815/4885 |
| US-20020143052-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | EPHX2 3403/4885TSHR 3723/4885NPC1 472/4885 |
| US-20030125306-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC9 | EPHX2 3403/4885TSHR 3723/4885NPC1 472/4885 |
| US-20020143196-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC5 | EPHX2 3291/4885TSHR 4235/4885NPC1 518/4885 |
| US-20020143037-A1 | Histone deacetylase inhibitors | HDAC1, HDAC9, HDAC11 | EPHX2 3469/4885TSHR 3706/4885NPC1 395/4885 |
| US-20020081646-A1 | Production method of polyhydroxyalkanoate form substituted fatty acid ester as raw material | FASN, FFAR1, ACADM | EPHX2 208/4885TSHR 3203/4885NPC1 2248/4885 |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | HCCS, CCL11, BCAT1 | EPHX2 2009/4885TSHR 3796/4885NPC1 837/4885 |
| US-20150344486-A1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, DTYMK, TK1 | EPHX2 2721/4885TSHR 3695/4885NPC1 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.